Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim of this study is to assess the prevalence of diabetes in patients attending a multidisciplinary consultation for fall risk assessment and to compare fall risk factors and the prevalence of other geriatric syndromes in patients with and without diabetes. A single-center retrospective cohort study was conducted at the Lille University Hospital Geriatrics Department, France. Inclusion criteria were any patients aged 65 years and over consulting for fall risk assessment between January 2, 2005, and January 2, 2015. A comprehensive multidisciplinary clinical evaluation was carried out to establish a personalized assessment of the patient's risk of falling. One thousand five hundred and twenty patients were included. Mean age was 81.4 ± 6.4 years; 72.2% were female, and 20% had diabetes. While patients with diabetes were younger than patients without diabetes (mean age: 79.4 ± 6.1 years vs. 81.9 ± 6.4 years, < 0.001), they were more likely to have had at least two falls in the previous 6 months (65.5% vs. 56.2%; = 0.004), had more balance and gait disorders (respectively, 77.4% vs. 69.7%, = 0.009, and 88% vs. 82%, = 0.012), and had more cognitive decline, urinary disorders, functional dependency, and polypharmacy than patients without diabetes ( < 0.0001 for all). Patients with diabetes have more geriatric syndromes and comorbidities, leading to a higher risk of adverse events compared to patients without diabetes even if they are younger. Preventing falls and other geriatric syndromes should therefore be a concern for all healthcare professionals who care for people with diabetes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393927PMC
http://dx.doi.org/10.1155/jdr/6145818DOI Listing

Publication Analysis

Top Keywords

patients diabetes
24
fall risk
16
geriatric syndromes
16
diabetes
10
patients
9
risk factors
8
diabetes patients
8
risk assessment
8
diabetes younger
8
fall
5

Similar Publications

Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.

J Clin Invest

September 2025

Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.

Understanding the genetic causes of diseases affecting pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy and diabetes syndrome (MEDS) is a congenital disorder with two known aetiological genes, IER3IP1 and YIPF5. Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking.

View Article and Find Full Text PDF

3-O-sulfation of heparan sulfate (HS) is the key determinant for binding and activation of Antithrombin III (AT). This interaction is the basis of heparin treatment to prevent thrombotic events and excess coagulation. Antithrombin-binding HS (HSAT) is expressed in human tissues, but is thought to be expressed in the subendothelial space, mast cells, and follicular fluid.

View Article and Find Full Text PDF

Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.

Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.

View Article and Find Full Text PDF

Indigenous Peoples experience the highest age-adjusted prevalence of type 2 diabetes of any racial group in the U.S. Though the management of type 2 diabetes requires regular healthcare visits, North American Indigenous individuals with diabetes do not always utilize the healthcare available to them, and this lack of utilization may lead to poor health outcomes over time.

View Article and Find Full Text PDF

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.

View Article and Find Full Text PDF